304445-49-6

Basic information

• Product Name: 3-FLUORO-4-BROMO-ACETOPHENONE
• Synonyms: 3-FLUORO-4-BROMO-ACETOPHENONE;4-BROMO-3-FLUORO-ACETOPHENONE;1-(4-BroMo-3-fluorophenyl)ethanone;1-(4-broMo-3-fluorophenyl)ethan-1-one;Ethanone, 1-(4-broMo-3-fluorophenyl)-;3-Fluoro-4-bromo-caetophenone
• CAS NO: 304445-49-6
• Molecular Formula: C₈H₆BrFO
• Molecular Weight: 217.04
• Mol File: 304445-49-6.mol

Chemical Properties

• Boiling Point: 263.3℃
• Flash Point: 113.0℃
• Appearance: /Solid
• Density: 1.535
• Vapor Pressure: 0.0104mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 3-FLUORO-4-BROMO-ACETOPHENONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-FLUORO-4-BROMO-ACETOPHENONE(304445-49-6)
• EPA Substance Registry System: 3-FLUORO-4-BROMO-ACETOPHENONE(304445-49-6)

Safety Data

• Hazardous Substances Data: 304445-49-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoro-4-bromo-acetophenone is used as an intermediate in the synthesis of various drugs and pharmaceutical products. Its specific functional groups and structural features make it a valuable component in the development of new medications.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Fluoro-4-bromo-acetophenone serves as a reagent, facilitating the creation of a range of organic compounds through chemical reactions. Its presence can influence the outcome of these reactions, leading to the formation of desired products.
Used in Specialty Chemicals Production:
3-Fluoro-4-bromo-acetophenone is also used as a building block in the production of specialty chemicals. Its unique combination of fluorine and bromine atoms provides it with properties that are useful in creating specific types of chemical products.
Safety Note:
Given its potentially hazardous nature, 3-Fluoro-4-bromo-acetophenone should be handled and stored with care, adhering to proper safety protocols to ensure the safety of individuals and the environment.

InChI:InChI=1/C8H6BrFO/c1-5(11)6-2-3-7(9)8(10)4-6/h2-4H,1H3

Upstream product

• 75-16-1 methylmagnesium bromide 
• 343564-56-7 4-bromo-3-fluoro-N-methoxy-N-methyl-benzamide 
• 133059-43-5 4-bromo-3-fluorobenzaldehyde 
• 153556-42-4 4-bromo-3-fluorobenzoic acid 
• 897016-95-4 (4-bromo-3-fluorophenyl)(morpholino)methanone 
• 676-58-4 methylmagnesium chloride 

Downstream Products

• 1006875-89-3 1-(4-bromo-3-fluorophenyl)-2,2-dihydroxyethanone 
• 1159186-70-5 5-(4-bromo-3-fluorophenyl)-1-methyl-1H-pyrazole 
• 928304-44-3 1-bromo-4-ethyl-2-fluorobenzene 
• 153556-42-4 4-bromo-3-fluorobenzoic acid 
• 1175528-91-2 2-(4-bromo-3-fluorophenyl)pyrrolidine 

Relevant articles and documents

ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR

Disclosed are compounds inhibiting the conversion of α–KG to D-2-HG, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition c

NOVEL BENZIMIDAMIDES COMPOUNDS COMPRISING AN OXABORININ RING

The invention relates to 4-(1-hydroxy-3,4-dihydro-1H-benzo[c][1,2]oxaborinin-3-yl)benzimidamide derivatives and their use in treating diseases and conditions of the skin (for example, Netherton syndrome, rosacea, atopic dermatitis, psoriasis and itch) cau

HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS

A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

Synthesis method of 3-fluoro-4-bromo-acetophenone

The invention relates to a synthesis method of 3-fluoro-4-bromo-acetophenone. The method includes: taking 3-fluoro-4-bromo-benzoyl chloride, dimethylhydroxyamine hydrochloride and methylmagnesium chloride as the raw materials, carrying out aminolysis, ext

NOVEL AROMATIC COMPOUND AND USE THEREOF

Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or To treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.

3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH

The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

HEPATITIS C INHIBITOR COMPOUNDS

Compounds of Formula (I) and (II) wherein R1, R2, R3, R6, A and A' are defined herein. The compounds are useful as inhibitors of the function of NS5A protein encoded by HCV for the treatment of hepatitis C viral infection.

IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS

The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.

PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS

The invention relates to compounds of formula (I) processes for their preparation, their use as 5-lipoxygenase inhibitors and pharmaceutical compositions containing the same.

SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME

The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.